ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Moderate Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has earned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $177.25.

Several analysts have recently weighed in on ICUI shares. Raymond James raised their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp increased their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Finally, StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th.

ICU Medical Stock Performance

Shares of ICUI opened at $165.59 on Friday. ICU Medical has a 12-month low of $85.64 and a 12-month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market cap of $4.05 billion, a PE ratio of -36.23 and a beta of 0.62. The stock has a 50-day moving average price of $171.48 and a 200-day moving average price of $150.56.

Insider Transactions at ICU Medical

In related news, COO Christian B. Voigtlander sold 1,430 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares of the company’s stock, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,364 shares of company stock worth $6,869,878. Insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Innealta Capital LLC purchased a new position in shares of ICU Medical in the 2nd quarter worth about $32,000. Hexagon Capital Partners LLC increased its stake in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares in the last quarter. Allworth Financial LP raised its holdings in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of ICU Medical during the second quarter valued at approximately $70,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.